GlassScriptPhysician profile
Hassan Farooq
NPI 1154370179
$2,393.19
in general payments reported to CMS, 2019-2025
31 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $18.15 · 2021: $97.81 · 2022: $246 · 2023: $138 · 2024: $479 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $545.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $294.51 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $232.77 | 2019-2022 | |
| Depuy Synthes Sales INC. | $149.70 | 2024 | Na |
| Abbott Laboratories | $144.21 | 2022-2025 | Aveir, Proclaim, Confirm Rx |
| Amarin Pharma, INC. | $124.21 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.46 | 2024 | Lifevest |
| Pfizer INC. | $114.92 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $88.83 | 2024-2025 | |
| Amgen INC. | $87.49 | 2019-2024 | Otezla, Repatha |
| Avanir Pharmaceuticals, INC. | $70.12 | 2022 | |
| Boston Scientific Corporation | $41.30 | 2022-2024 | Watchman Flx |
| Corcept Therapeutics | $37.03 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $32.48 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $30.73 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.15 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $29.42 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2024 | Camzyos |
| Astellas Pharma US INC | $20.81 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.63 | 2021 | |
| Dexcom, INC. | $18.95 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $18.26 | 2021 | |
| Exact Sciences Corporation | $16.68 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.07 | 2023 | Rexulti |
| Lilly USA, LLC | $16.01 | 2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $15.31 | 2022 | |
| Celgene Corporation | $15.30 | 2019 | |
| Insulet Corporation | $13.11 | 2021 | |
| Allergan, INC. | $13.07 | 2019 | |
| Athena Bioscience, LLC | $12.17 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.